)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Editas Medicine
Editas Medicine (EDIT) investor relations material
Editas Medicine Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
Q3 2026 collaboration and other R&D revenue was $10.4M, up 37% YoY; net loss narrowed to $23.4M from $25.1M.
EDIT-401 advanced toward first-in-human dosing in 2026; cash and marketable securities of $190.2M supported an expected runway into H2 2028.
Financial highlights
Q3 revenue was $10.4M versus $7.5M, primarily reflecting a strategic partner milestone; operating loss was $24.3M versus $24.5M.
Q3 R&D expense was $21.2M versus $19.8M, and G&A expense was $13.5M versus $12.3M YoY.
9M revenue was $25.1M versus $15.8M; net loss was $66.6M versus $154.4M, with 2025 including $66.9M of restructuring and impairment charges.
9M operating cash use was $73.8M versus $128.9M; financing provided $117.1M, primarily from the May offering.
Outlook and guidance
EDIT-401 Strive patient dosing remained on track for 2026; initial safety and tolerability data were expected in Q1 2027, with Part 1 topline safety and efficacy results targeted for H2 2027.
Cash, cash equivalents and marketable securities at September 30 were expected to fund operating expenses and capital expenditures into H2 2028; the forecast is subject to assumptions and could vary materially.
R&D expenses were expected to increase to support EDIT-401 clinical development and other preclinical programs; profitability was not expected in FY 2026 or the foreseeable future.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Editas Medicine
- EDIT-401 aims for 90% LDL reduction, with first dosing this year and safety data in Q1 next year.EDIT
12th Annual Cantor Fitzgerald Global Healthcare Conference - EDIT-401, an in vivo CRISPR therapy for LDL reduction, enters clinical trials this year.EDITWells Fargo 21st Annual Healthcare Conference
- Shelf registration allows up to $400M in offerings, including $150M ATM sales for gene editing R&D.EDITRegistration filing
- EDIT-401 advances with robust preclinical data as net loss narrows and cash rises to $211.6M.EDITQ2 2026
- Pivoting to in vivo gene editing, with proof of concept achieved and cash runway to Q2 2027.EDITStrategy Update
- In vivo gene editing and reni-cel partnership drive strategic focus, with strong financial runway.EDITStifel 2024 Healthcare Conference
- CRISPR-based LDLR upregulation shows 90% LDL reduction, with human trials set for 2026.EDITEvercore ISI 8th Annual HealthCONx Conference
- Q2 net loss widened to $67.6M as R&D spending surged; cash runway extends into 2026.EDITQ2 2024
- Reniz-cel shows strong efficacy as the company advances in vivo editing and IP monetization strategies.EDITMorgan Stanley 22nd Annual Global Healthcare Conference
Next Editas Medicine earnings date
3rd Annual Guggenheim Healthcare Innovation Conference10 Nov, 2026
Editas Medicine
Next Editas Medicine earnings date
3rd Annual Guggenheim Healthcare Innovation Conference10 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Editas Medicine, a genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company seeks to address the fundamental flaws in existing approaches to genetic and infectious diseases by developing TALEN and CRISPR genome editing systems that function more efficiently than existing technologies. It has invented lymphocyte-directed gene therapy that uses CRISPR/Cas9 technology to manufacture a novel endonuclease. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.